June 23, 2017 4:36 AM ET

Healthcare Providers and Services

Company Overview of National Cancer Center

Company Overview

National Cancer Center operates as a hospital that focuses on cancer treatment and clinical research services. The company provides patient care services, which include maintenance of clinics and wards, diagnosis and treatment by means of diagnostic tools, proton therapy, palliative care, and volunteering activities. Its research institute offers development of treatment methods and diagnostic procedures. The company's oncology research and clinical trial center unites doctors and researchers for development of drugs and medical equipment. In addition, it gathers and disseminates cancer related information to community and recommends initiatives and policies to government. National Cancer Ce...

5-1-1 Tsukiji


Tokyo,  104-0045


Founded in 1962


81 3 3542 2511

Key Executives for National Cancer Center

Chief-Office-Advncd Medical Careevaluation & Health Tech assessment & Director-Strategic Planning
Chief of Research Audit Section and Director of Center for Researchadministration and Support
Director of Administrative Departments
Director of Center for Education Andprofessional Career Development
Compensation as of Fiscal Year 2016.

National Cancer Center Key Developments

Daiichi Sankyo (Japan) Enters into Collaboration with National Cancer Center of Japan

Daiichi Sankyo (Japan) has entered into a collaboration with the National Cancer Center of Japan to develop an inhibitor for DS-1001 (mutant isocitrate dehydrogenase IDH1) as a new treatment for gliomas (malignant brain tumours), the parties said in a statement. In addition, the two parties aim to initiate a multi-centre Phase I clinical trial of DS-1001 in patients with recurrent IDH1 mutant gliomas who have no standard treatment. IDH1 and IDH2 gene mutations are frequently observed in patients with malignant tumours such as gliomas, acute myeloid leukaemia (AML), cholangiocarcinoma, and chondrosarcoma. IDH1 gene mutations are observed in more than 70% of patients diagnosed as grade 2 or 3 gliomas (astrocytomas or oligodendrogliomas), with cases most frequently observed in people aged 30-50 years. The collaboration agreement follows research by the National Cancer Center Research Institute's showing that inhibition of mutant IDH1/2 was able to eliminate AML cancer stem cells, and preclinical studies also demonstrated that DS-1001 was effective in suppressing the proliferation of AML, malignant gliomas, and chondrosarcoma. The collaboration reflects a growing trend of corporate-academia partnerships in Japan, which have the advantage of aligning academic research more closely with market and patient demand, as well as corporate funding. In particular, the agreement further extends Japan's National Cancer Center's series of collaborations.

Similar Private Companies By Industry

Company Name Region
Accuthera Inc. Asia
Actec Co., Ltd. Asia
Active Care Co., Ltd. Asia
Aiseikai, Foundation Asia
Aishinkai Medical Association Asia

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact National Cancer Center, please visit www.ncc.go.jp. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.